Pair Name	Saikosaponin D, Gefitinib
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Phosphorylation	STAT3	hsa6774
In Vitro Model	NCI-H1975	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_1511
	HCC827	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_2063
	PC-9	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_B260
	HCC827-GR-high1	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_S703
	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
In Vivo Model	Mice were intraperitoneally injected with HCC827/GR (1×10⁷) cells in the dorsal region.
Result	These results indicated that the combination of SSD with gefitinib had an increased antitumor effect in NSCLC cells and that the molecular mechanisms were associated with the inhibition of STAT3/Bcl-2 signaling pathway. Our findings suggest a promising approach for the treatment of NSCLC patients with EGFR-TKI resistance.

Pair Name	Saikosaponin D, Gefitinib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Glycolysis
Gene Regulation	Down-regulation	Expression	ABCC1	hsa4363
	Down-regulation	Expression	ABCG2	hsa9429
	Down-regulation	Expression	ADRB2	hsa154
	Down-regulation	Expression	HK2	hsa3099
	Down-regulation	Expression	HK2	hsa3099
	Down-regulation	Expression	SLC2A1	hsa6513
	Down-regulation	Expression	SLC2A1	hsa6513
In Vitro Model	RBE	Intrahepatic cholangiocarcinoma	Homo sapiens (Human)	CVCL_4896
	HuCC-T1	Intrahepatic cholangiocarcinoma	Homo sapiens (Human)	CVCL_0324
Result	Saikosaponin D enhances the antitumor effect of gemcitabine by controlling glucose metabolism and drug efflux by inhibiting the ADRB2 signaling. Therefore, the combination of saikosaponin D and gemcitabine may be a potential therapeutic strategy for the treatment of iCCA.